437 related articles for article (PubMed ID: 29030331)
1. On OX40 and PD-1 Combination: Why Should OX40 Be First in Sequence?
Colombo MP
Clin Cancer Res; 2017 Oct; 23(20):5999-6001. PubMed ID: 29030331
[TBL] [Abstract][Full Text] [Related]
2. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
3. An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.
Wang R; Gao C; Raymond M; Dito G; Kabbabe D; Shao X; Hilt E; Sun Y; Pak I; Gutierrez M; Melero I; Spreafico A; Carvajal RD; Ong M; Olszanski AJ; Milburn C; Thudium K; Yang Z; Feng Y; Fracasso PM; Korman AJ; Aanur P; Huang SA; Quigley M
Clin Cancer Res; 2019 Nov; 25(22):6709-6720. PubMed ID: 31573956
[TBL] [Abstract][Full Text] [Related]
4. Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities.
Cousin S; Italiano A
Clin Cancer Res; 2016 Sep; 22(18):4550-5. PubMed ID: 27435397
[TBL] [Abstract][Full Text] [Related]
5. Anti-CD137 and PD-1/PD-L1 Antibodies En Route toward Clinical Synergy.
Pérez-Ruiz E; Etxeberria I; Rodriguez-Ruiz ME; Melero I
Clin Cancer Res; 2017 Sep; 23(18):5326-5328. PubMed ID: 28790118
[TBL] [Abstract][Full Text] [Related]
6. Clinical Development of PD-1/PD-L1 Immunotherapy for Gastrointestinal Cancers: Facts and Hopes.
Chau I
Clin Cancer Res; 2017 Oct; 23(20):6002-6011. PubMed ID: 28615369
[TBL] [Abstract][Full Text] [Related]
7. Combinations of Bevacizumab With Cancer Immunotherapy.
Chen DS; Hurwitz H
Cancer J; 2018; 24(4):193-204. PubMed ID: 30119083
[TBL] [Abstract][Full Text] [Related]
8. Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer.
Schmidt EV
Semin Immunopathol; 2019 Jan; 41(1):21-30. PubMed ID: 30374524
[TBL] [Abstract][Full Text] [Related]
9. Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy.
Wu X; Giobbie-Hurder A; Liao X; Connelly C; Connolly EM; Li J; Manos MP; Lawrence D; McDermott D; Severgnini M; Zhou J; Gjini E; Lako A; Lipschitz M; Pak CJ; Abdelrahman S; Rodig S; Hodi FS
Cancer Immunol Res; 2017 Jan; 5(1):17-28. PubMed ID: 28003187
[TBL] [Abstract][Full Text] [Related]
10. What Have We Got to Lose?
McNeil CM
J Clin Oncol; 2016 Dec; 34(36):4443-4444. PubMed ID: 27998220
[No Abstract] [Full Text] [Related]
11. The clinical added value of the addition of anti-CTL-4 to anti-PD-1 alone is questionable and clearly increasing toxicity regarding pivotal studies in the treatment of melanoma and renal carcinoma.
Albin N; Monard A; Lapiere J
Cancer Chemother Pharmacol; 2019 May; 83(5):1003-1005. PubMed ID: 30830289
[No Abstract] [Full Text] [Related]
12. Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer.
Dong J; Li B; Zhou Q; Huang D
J Evid Based Med; 2018 Nov; 11(4):278-287. PubMed ID: 30444051
[TBL] [Abstract][Full Text] [Related]
13. In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
Aspeslagh S; Matias M; Palomar V; Dercle L; Lanoy E; Soria JC; Postel-Vinay S
Eur J Cancer; 2017 Dec; 87():65-74. PubMed ID: 29126088
[TBL] [Abstract][Full Text] [Related]
14. PDL-1/PD1 inhibitors: antibody or antinobody?
Aoun F; Rassy EE; Assi T; Kattan J
Future Oncol; 2017 Aug; 13(19):1669-1671. PubMed ID: 28831825
[No Abstract] [Full Text] [Related]
15. Programmed cell death protein-1 inhibitor for the treatment of hepatocellular carcinoma: "A sharp sword".
Li X; Liang P; Ye X
J Cancer Res Ther; 2019; 15(2):267-268. PubMed ID: 30964095
[No Abstract] [Full Text] [Related]
16. Challenges faced when identifying patients for combination immunotherapy.
Ernstoff MS; Gandhi S; Pandey M; Puzanov I; Grivas P; Montero A; Velcheti V; Turk MJ; Diaz-Montero CM; Lewis LD; Morrison C
Future Oncol; 2017 Aug; 13(18):1607-1618. PubMed ID: 28835114
[TBL] [Abstract][Full Text] [Related]
17. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model.
Niknam S; Barsoumian HB; Schoenhals JE; Jackson HL; Yanamandra N; Caetano MS; Li A; Younes AI; Cadena A; Cushman TR; Chang JY; Nguyen QN; Gomez DR; Diab A; Heymach JV; Hwu P; Cortez MA; Welsh JW
Clin Cancer Res; 2018 Nov; 24(22):5735-5743. PubMed ID: 29784675
[No Abstract] [Full Text] [Related]
18. Masterful Antibodies: Checkpoint Blockade.
Lonberg N; Korman AJ
Cancer Immunol Res; 2017 Apr; 5(4):275-281. PubMed ID: 28373215
[TBL] [Abstract][Full Text] [Related]
19. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
Maxwell R; Jackson CM; Lim M
Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulatory effects of current cancer treatment and the consequences for follow-up immunotherapeutics.
Mooradian MJ; Sullivan RJ
Future Oncol; 2017 Aug; 13(18):1649-1663. PubMed ID: 28776423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
